NEET-PG 2015 - Pharmacology Practice Questions

Q: Which of the following drugs is NOT metabolized by acetylation?

Metoclopramide. ***Metoclopramide*** - **Metoclopramide** is eliminated primarily via renal excretion, with a smaller portion undergoing glucuronidation and sulfation, not acetylation. - Its metabolic pathway does not involve the enzyme **N-acetyltransferase**, which is responsible for acetylation. *Dapsone* - **Dapsone** undergoes significant **N-acetylation** by NAT2 (N-acetyltransferase 2), which is important for its metabolism and clearance. - Genetic variations in NAT2 can lead to individual differences in **dapsone acetylation rates**, affecting drug efficacy and toxicity. *Procainamide* - **Procainamide** is primarily metabolized by N-acetyltransferase 2 (NAT2) to **N-acetylprocainamide (NAPA)**, an active metabolite. - Differences in **acetylation phenotype** (slow vs. rapid acetylators) influence the metabolism of procainamide and the risk of drug-induced lupus. *INH* - **Isoniazid (INH)** is extensively metabolized in the liver, primarily by **N-acetylation** via the enzyme N-acetyltransferase 2 (NAT2). - The rate of INH acetylation varies significantly among individuals, classifying them as **slow or rapid acetylators**, which impacts drug toxicity and efficacy.

Q: Which sympathomimetic drug is primarily known to increase heart rate?

Isoprenaline. ***Isoprenaline*** - **Isoprenaline** (isoproterenol) is a non-selective beta-adrenergic agonist, with a strong affinity for **β1 and β2 receptors** [1]. - Its activation of **β1 receptors** in the heart leads to a significant increase in **heart rate (positive chronotropy)** and contractility (positive inotropy) [1]. - It is the **most potent chronotropic agent** among sympathomimetics and is primarily known for increasing heart rate [2]. *Phenylephrine* - **Phenylephrine** is a selective **α1 adrenergic agonist** that causes vasoconstriction [4]. - It increases blood pressure but typically causes **reflex bradycardia** (decreased heart rate) due to baroreceptor activation. - Does NOT directly increase heart rate. *Noradrenaline* - **Noradrenaline** (norepinephrine) primarily acts on **α1 receptors** causing vasoconstriction, and to a lesser extent on **β1 receptors** [3]. - While it can stimulate β1 receptors, its predominant effect is to increase **mean arterial pressure** through vasoconstriction, often causing **reflex bradycardia** [3]. *Adrenaline* - **Adrenaline** (epinephrine) acts on **α1, β1, and β2 receptors** [4]. While it does increase heart rate via **β1 receptor** stimulation, it also causes significant **vasoconstriction** (via α1) and **vasodilation** (via β2). - Its cardiovascular effects are more complex and dose-dependent compared to isoprenaline's specific chronotropic action.

Q: Permission from DCGI [Drug controller general, India] is needed before which phase of drug trial?

Phase 3. ***Phase 3*** - Permission from the **DCGI (Drug Controller General of India)** is mandatory before initiating **Phase 3** clinical trials as per **Schedule Y** of the Drugs and Cosmetics Rules. - Phase 3 trials involve **large-scale studies in Indian patients** to establish efficacy and safety in the target population, requiring explicit regulatory approval. - This is the critical regulatory checkpoint where DCGI evaluates the Phase 1 and 2 data before allowing widespread testing in Indian subjects. *Phase 1* - Phase 1 trials can be conducted after approval from the **Institutional Ethics Committee (IEC)** without requiring prior DCGI permission. - These trials in healthy volunteers focus on safety, pharmacokinetics, and dose-ranging studies. - DCGI is informed but explicit permission is not mandatory at this stage. *Phase 2* - Phase 2 trials also proceed with **IEC approval** and do not require prior DCGI permission. - These trials evaluate therapeutic efficacy and dose determination in a limited number of patients. - Results from Phase 2 are submitted to DCGI when seeking Phase 3 approval. *Phase 4* - Phase 4 trials are **post-marketing surveillance** studies conducted after drug approval. - These are conducted under the Post-Marketing Surveillance (PMS) framework. - While regulatory oversight exists, these are not pre-market trials requiring permission to initiate.

Q: Which ACE inhibitor is safe in renal failure?

Benazepril. ***Benazepril*** - Among the listed ACE inhibitors, benazepril has the **most favorable excretion profile** in renal failure with approximately **50% renal and 50% hepatic elimination** (dual excretion pathway). - This balanced elimination reduces the risk of drug accumulation compared to predominantly renally excreted ACE inhibitors. - While dose adjustment may still be needed in **severe renal impairment**, benazepril is considered the **safest option among those listed** for patients with renal dysfunction. - **Note:** Fosinopril (not listed here) has true 50/50 dual elimination and requires no dose adjustment in renal failure, making it the ideal choice in clinical practice. *Captopril* - This ACE inhibitor undergoes predominantly **renal excretion (95%)** as unchanged drug and metabolites. - Requires significant **dose reduction** in renal failure to prevent accumulation and adverse effects including **hyperkalemia** and **hypotension**. - Less safe than benazepril in renal impairment due to heavy dependence on renal elimination. *Enalapril* - Enalapril is a prodrug converted to **enalaprilat**, with approximately **90% renal excretion**. - Dose adjustment is mandatory based on **creatinine clearance** in patients with renal failure. - Higher risk of accumulation and toxicity compared to dual-elimination ACE inhibitors like benazepril.

Q: Which of the following is non-selective 3rd generation Beta blocker ?

Carvedilol. ***Carvedilol*** - **Carvedilol** is a **non-selective beta-adrenergic antagonist** (blocks both β1 and β2 receptors) with **additional α1-adrenergic blocking activity**, making it a true **3rd generation beta-blocker**. - The α1-blockade provides **vasodilatory properties**, reducing peripheral vascular resistance and improving hemodynamics. - It has favorable effects on lipid metabolism and insulin sensitivity, making it particularly useful in heart failure and hypertension. - Its non-selective beta-blockade combined with vasodilation distinguishes it from selective 3rd generation agents. *Betaxolol* - **Betaxolol** is a **selective β1-adrenergic antagonist** without vasodilatory properties. - Classified as a **2nd generation beta-blocker** due to its cardioselectivity. - Primarily used in glaucoma and hypertension but lacks the non-selective profile and additional mechanisms of 3rd generation agents. *Celiprolol* - **Celiprolol** is a **β1-selective antagonist** with **β2-agonistic effects** providing vasodilation. - While classified as 3rd generation due to vasodilatory properties, it is **selective for β1**, not non-selective. - Its β2-agonism causes peripheral vasodilation but maintains β1-selectivity. *Nebivolol* - **Nebivolol** is a highly **selective β1-adrenergic antagonist** with **vasodilatory effects via nitric oxide (NO) release**. - Classified as 3rd generation due to NO-mediated vasodilation, but it is **β1-selective**, not non-selective. - The combination of high β1-selectivity and endothelial-mediated vasodilation makes it unique among 3rd generation agents.

Q: Which of the following agents requires the MOST caution when combined with spironolactone due to increased risk of hyperkalemia:

ACE inhibitors. ***ACE inhibitors*** - Spironolactone is a **potassium-sparing diuretic** that increases potassium levels by blocking aldosterone's effects in the collecting duct [1]. - **ACE inhibitors** also decrease aldosterone production [2], leading to reduced potassium excretion and a significant risk of **severe hyperkalemia** when combined with spironolactone [1, 2].*Beta-blockers* - While beta-blockers can cause a slight increase in plasma potassium by inhibiting cellular potassium uptake, this effect is generally modest and does not pose a major hyperkalemia risk when co-administered with spironolactone. - Their primary interaction concerns blood pressure and heart rate, not direct potassium handling.*Amlodipine* - Amlodipine is a **calcium channel blocker** that primarily causes vasodilation and does not significantly alter potassium balance. - Therefore, it does not substantially increase the risk of hyperkalemia when used concurrently with spironolactone.*Chlorothiazide* - Chlorothiazide is a **thiazide diuretic** that promotes potassium excretion, leading to a risk of hypokalemia. - When combined with spironolactone, a potassium-sparing diuretic, these agents can **partially offset each other's effects** on potassium balance, potentially reducing the risk of hyperkalemia compared to ACE inhibitors.

Q: Beta-blockers should be used with caution in patients with?

Conduction defect. ***Conduction defect*** - Beta-blockers **slow heart rate** and **decrease AV nodal conduction**, which can worsen pre-existing conduction defects like **AV block** or **sick sinus syndrome**. - Their use can lead to **symptomatic bradycardia** or complete heart block in susceptible individuals. - This represents a **strong relative contraindication** requiring significant caution. *Hypertension* - Beta-blockers are a **first-line treatment for hypertension**, effectively lowering blood pressure by reducing cardiac output and renin release. - They are generally **well-tolerated** and beneficial in most hypertensive patients. *Glaucoma* - Topical beta-blockers, such as **timolol**, are a common treatment for open-angle glaucoma as they **reduce aqueous humor production**, thereby lowering intraocular pressure. - Systemic use of beta-blockers does not typically worsen glaucoma and may even offer some benefit. *CHF* - While certain beta-blockers (**carvedilol, metoprolol succinate, bisoprolol**) are now proven beneficial in **chronic heart failure with reduced ejection fraction (HFrEF)**, they do require careful use. - They must be **initiated at low doses and carefully titrated** to avoid acute decompensation, and are **contraindicated in acute decompensated heart failure**. - However, **conduction defects** represent a **stronger contraindication** where beta-blockers can cause life-threatening bradycardia or complete heart block, making it the best answer for conditions requiring the most caution.

Q: At which receptor is the primary action of antipsychotic medications required?

D2 dopaminergic. ***D2 dopaminergic*** - The **antipsychotic effects** of typical (first-generation) antipsychotics are primarily mediated through **D2 receptor blockade** [1]. - Blocking D2 receptors in the **mesolimbic pathway** helps reduce positive symptoms of psychosis like hallucinations and delusions [2]. *M, muscarinic* - **Muscarinic receptor blockade** is a common adverse effect of some antipsychotics, leading to anticholinergic side effects such as **dry mouth** and **blurred vision**, rather than their primary therapeutic action. - This action does not directly contribute to the antipsychotic effect. *D1 dopaminergic* - While D1 receptors are involved in dopamine signaling, they are **not the primary target** for the antipsychotic action of most drugs [1]. - Some atypical antipsychotics may affect D1 receptors, but it's secondary to their D2 antagonism and serotonin modulation. *5HT4 serotonergic* - **Serotonin receptors (5HT)**, particularly 5HT2A, are important targets for atypical (second-generation) antipsychotics. - However, 5HT4 receptors are **not a primary target** for the antipsychotic effects, and 5HT2A blockade modulates dopamine release, which is still connected to the D2 hypothesis.

Q: Which diuretic is most likely to cause hyponatremia by impairing free water excretion?

Thiazide diuretics. ***Thiazide diuretics*** - **Thiazide diuretics** inhibit the **Na-Cl cotransporter in the distal convoluted tubule (DCT)**, impairing the kidney's ability to dilute urine and excrete free water - This impaired urinary dilution leads to **water retention relative to sodium**, resulting in **dilutional hyponatremia** - **Most common in elderly patients**, those on low-salt diets, or with pre-existing volume depletion - **Mechanism**: By blocking sodium reabsorption in the DCT (a key site for urinary dilution), thiazides prevent the generation of free water, leading to hyponatremia when water intake continues *Loop diuretics* - **Loop diuretics** inhibit the **Na-K-2Cl cotransporter in the thick ascending limb of Henle**, causing significant diuresis - They impair the medullary concentration gradient, **enhancing free water excretion** - **Less likely to cause hyponatremia** compared to thiazides because they promote rather than impair free water clearance - When hyponatremia occurs with loop diuretics, it's usually due to concurrent SIADH or excessive free water intake *Acetazolamide* - **Acetazolamide** is a **carbonic anhydrase inhibitor** acting primarily on the **proximal tubule** - Causes **bicarbonate and sodium excretion**, leading to mild diuresis - Main side effect is **metabolic acidosis** (type 2 RTA) - **Does not significantly impair free water excretion**, making hyponatremia uncommon *Amiloride* - **Amiloride** is a **potassium-sparing diuretic** that blocks **epithelial sodium channels (ENaC) in the collecting duct** - Weak diuretic effect, primarily used to prevent potassium loss - **Does not impair urinary dilution mechanisms**, so hyponatremia is rare - Main concern is **hyperkalemia**, especially with ACE inhibitors or in renal insufficiency

Question 1

Which of the following drugs is NOT metabolized by acetylation?

Accepted Answer

Metoclopramide

Answer

Dapsone

Answer

Procainamide

Answer

INH

Question 2

Which sympathomimetic drug is primarily known to increase heart rate?

Accepted Answer

Isoprenaline

Answer

Phenylephrine

Answer

Noradrenaline

Answer

Adrenaline

Question 3

Permission from DCGI [Drug controller general, India] is needed before which phase of drug trial?

Accepted Answer

Phase 3

Answer

Phase 1

Answer

Phase 2

Answer

Phase 4

Question 4

Which ACE inhibitor is safe in renal failure?

Accepted Answer

Benazepril

Answer

Captopril

Answer

Enalapril

Answer

None of the options

Question 5

Which of the following is non-selective 3rd generation Beta blocker ?

Accepted Answer

Carvedilol

Answer

Betaxolol

Answer

Celiprolol

Answer

Nebivolol

Question 6

Which of the following agents requires the MOST caution when combined with spironolactone due to increased risk of hyperkalemia:

Accepted Answer

ACE inhibitors

Answer

Beta-blockers

Answer

Amlodipine

Answer

Chlorothiazide

Question 7

Beta-blockers should be used with caution in patients with?

Accepted Answer

Conduction defect

Answer

Hypertension

Answer

CHF

Answer

Glaucoma

Question 8

At which receptor is the primary action of antipsychotic medications required?

Accepted Answer

D2 dopaminergic

Answer

M, muscarinic

Answer

5HT4 serotonergic

Answer

D1 dopaminergic

Question 9

What is the primary mechanism of action of opioids in pain management?

Accepted Answer

Activation of opioid receptors at both spinal and supraspinal levels

Answer

Inhibition of cyclooxygenase (COX) enzymes

Answer

Activation of opioid receptors in the spinal cord only

Answer

Activation of opioid receptors in the brain only

Question 10

Which diuretic is most likely to cause hyponatremia by impairing free water excretion?

Accepted Answer

Thiazide diuretics

Answer

Loop diuretics

Answer

Acetazolamide

Answer

Amiloride

NEET-PG 2015 — Pharmacology